

Nova Pharmaceutical Corporation

[View the current Nova Pharmaceutical Corporation Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/7638-Nova+Pharmaceutical+Corporation.html)

(<http://www.bioportfolio.com/bi corporate/7638-Nova+Pharmaceutical+Corporation.html>)

Contact Details:

Tel: 410 558 7000

Fax: 410 522 7199

Email:

MD

United States of America

Recent Publications by Nova Pharmaceutical Corporation:



- [Effects of strychnine-insensitive glycine receptor antagonists and sigma agents on working memory performance: comparison with dizocilpine and scopolamine.](#)

The strychnine insensitive glycine receptor antagonists (+/-) HA 966 (2.5,...27th February, 2001 Nova Pharmaceutical Corporation, 6200 Freeport Centre, Baltimore, MD- Behav Pharmacol. 1992 Aug;3(4):393-402.

Press Releases on Nova Pharmaceutical Corporation:

[Heska Announces Supply Agreement With Roche Diagnostics](#)

25th November,
2009

Heska Corporation

LOVELAND, Colo., Nov. 25 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq: HSKA); ("Heska"), a leading provider of advanced diagnostic and specialty products to the veterinary industry,

Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam	25th November, 2009	Maryland Technology Enterprise Institute	COLLEGE PARK, Md., Nov. 25 /PRNewswire-USNewswire/ -- <i>Remedium Technologies Inc., a company developing a shaving cream-like foam that stops severe bleeding, won first prize and \$10,000 in the Most</i>
Video: Genworth Recognizes the Nation's Caregivers in New Ad Campaign	25th November, 2009	Genworth Financial	RICHMOND, Va., Nov. 25 /PRNewswire-FirstCall/ -- <i>There are 120 million reasons to recognize caregivers in the U.S., and Genworth Financial (NYSE: GNW) will celebrate and give thanks to these men and</i>
China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits	25th November, 2009	China Sky One Medical, Inc.	HARBIN, China, Nov. 25 /PRNewswire-Asia-FirstCall/ -- <i>China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated</i>
AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit	25th November, 2009	AMPAC Fine Chemicals LLC	RANCHO CORDOVA, Calif., Nov. 25 /PRNewswire/ -- <i>AMPAC Fine Chemicals LLC (AFC), a subsidiary of American Pacific Corporation (Nasdaq: APFC) announced today that it received the Environmental</i>

BioNews Results for Nova Pharmaceutical Corporation



- [Insider trading probe at major PR firm: Kwan Communications provided Evogene with media and investor relations](#)
TradingMarkets: Nov 19 2009 9:34PM Matching: nova pharmaceutical
- [Insider trading probe at major PR firm](#)
Globes: Nov 19 2009 4:30PM Matching: nova pharmaceutical
- [Insider trading probe at Teva's PR firm](#)
Globes: Nov 19 2009 11:42AM Matching: nova pharmaceutical



Nova Pharmaceutical Corporation Patents:

- 5925377- [Dietary supplement composition](#)
- 5122367- [Polyanhydride bioerodible controlled release implants for administration of stabilized growth hormone](#)
- 5079260- [Method for treating inflammation and compounds and compositions suitable for use therein](#)
- 5063245- [Corticotropin-releasing factor antagonism compounds](#)
- 5049555- [Antagonists of specific excitatory amino acid receptors as neuroprotectants and anxiolytics](#)
- 4999417- [Biodegradable polymer compositions](#)
- 4997904- [Aromatic polyanhydride compositions](#)
- 4906638- [Dextromethorphan potentiator for anticonvulsant composition and method](#)
- 4889860- [Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists](#)
- 4761405- [Antagonists of specific excitatory amino acid neurotransmitter receptors having increased potency](#)
- 4760069- [Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists](#)
- 5135917- [Interleukin receptor expression inhibiting antisense oligonucleotides](#)
- 5171812- [Polyanhydrides of oligomerized unsaturated aliphatic acids](#)
- 5340588- [Liposphere carriers of vaccines](#)
- 5317079- [Fatty acid terminated polyanhydride](#)
- 5270419- [Polyanhydrides of oligomerized unsaturated aliphatic acids](#)
- 5240963- [Branched polyanhydrides](#)
- 5227165- [Liposphere delivery systems for local anesthetics](#)
- 5221535- [Sustained release formulations of insect repellent](#)
- 5189046- [Protein kinase C modulators](#)
- 5188837- [Lipspheres for controlled delivery of substances](#)
- 5179189- [Fatty acid terminated polyanhydrides](#)
- 5175235- [Branched polyanhydrides](#)
- 4657899- [Antagonists of specific excitatory amino acid neurotransmitter receptors](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic

- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

